Syntec Optics (OPTX) Q2 2025 earnings summary

Executive summary

• Strategy centers on leading the light-enabled products market with a diverse portfolio, advanced manufacturing, and in-house design for blue-chip customers across defense, medical, consumer, and communication sectors.

• Achieved record-high net sales in 2024, with continued growth in H1 2025 driven by strong demand in defense, biomedical, and communications end-markets.

• Recent product launches include lightweight night vision optics, biomedical mirrors, microlens arrays for satellite communications, and new light-enabled products for space-based solar power and fusion energy.

• Execution plan focuses on operational excellence, scaling production, automation, and expanding into new high-growth markets.

• Strengthened management team and invested $3.3 million in state-of-the-art equipment to support future growth.

Financial highlights

• Full-year 2024 net sales reached $28.4 million, up $1.9 million year-over-year; H1 2025 net sales were $13.6 million, up $0.3 million year-over-year.

• Q2 2025 net sales were $6.6 million, down 6.4% year-over-year; six-month sales rose 2.8% to $13.6 million.

• Adjusted EBITDA for 2024 was $2.2 million, down from $5.3 million in 2023; H1 2025 adjusted EBITDA margin rose to 15.3% from 5.8% in H1 2024.

• Gross margin improved from 22% in H1 2024 to 29% in H1 2025; Q2 2025 gross margin was 24%.

• Net income for H1 2025 improved by $0.9 million year-over-year, reaching breakeven; Q2 2025 net loss was $0.34 million.

Outlook and guidance

• Strategy targets operational excellence, scaling production, and expansion into new light-enabled markets and applications such as fusion energy and quantum computing.

• Plans to pursue bolt-on acquisitions for inorganic growth and expand into new end markets like communications and sensing.

• Management expects continued gross profit improvements as yields and efficiencies rise.